Kosan Biosciences Incorporated presented results from a Phase 1 clinical trial of its second-generation Hsp90 inhibitor, alvespimycin HCl , showing encouraging signs of anti-leukemia activity in a highly refractory patient population and tolerable toxicity.
No comments:
Post a Comment